Skip to main content
Algernon Health Inc. logo

Algernon Health Inc. — Investor Relations & Filings

Ticker · AGN ISIN · CA3978841078 CSE Human health and social work activities
Open in API
Filings indexed 579 across all filing types
Latest filing 2021-01-25 Capital/Financing Update
Country CA Canada
Listing CSE AGN

About Algernon Health Inc.

https://www.algernonhealth.com/

Algernon Health Inc. is a healthcare company focused on the provision of advanced diagnostic services, primarily through the establishment of medical clinics specializing in Alzheimer's disease. A key offering is the utilization of brain-optimized Positron Emission Tomography (PET) scanning technology for screening and imaging within a planned network of North American facilities. The company maintains a clinical-stage drug development and repurposing division, which investigates existing, approved drugs for new therapeutic applications targeting unmet global medical needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release from Algernon Pharmaceuticals providing a final summary on accelerated warrants. It discusses the exercise of warrants, capital contribution from warrant exercises, and the delisting of the warrants from the exchange. There is no detailed financial report, earnings data, or management discussion. The document is an announcement about financing activity related to warrants and their delisting. It is not a full financial report, audit, or earnings release. The content fits best under Capital/Financing Update (CAP) because it updates on the company's financing activities and capital structure changes related to warrant exercises and cancellations.
2021-01-25 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Algernon Pharmaceuticals has received approval from the Data and Safety Monitoring Board (DSMB) to proceed with the Phase 3 study of Ifenprodil for COVID-19. It discusses clinical trial progress and safety review but does not contain any financial data, regulatory filings, or detailed financial reports. It is an announcement related to clinical trial progress rather than a financial or regulatory report. The document length is about 5,382 characters, which is relatively short and consistent with a news or announcement release. There is no indication that this is a financial report, earnings release, or regulatory filing. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-01-19 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release from Algernon Pharmaceuticals highlighting an independent research review identifying Ifenprodil as a potential COVID-19 treatment. It discusses the research findings, the status of the company's clinical trial, and provides forward-looking statements. There are no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no earnings data, and no mention of any report being attached or published. The content is primarily an update on research and clinical trial progress, typical of a Capital/Financing Update or general company update. However, since it focuses on clinical trial progress and research highlights rather than fundraising or capital structure changes, it does not fit neatly into Capital/Financing Update (CAP). It is not a regulatory filing or announcement of a report. Given the nature of the content as a company update on research and clinical trial progress, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2021-01-11 English
News release - English.pdf
Regulatory Filings
2021-01-07 English
News release - English.pdf
Management Reports Classification · 95% confidence The document is a year-end summary of key activities by Algernon Pharmaceuticals, detailing clinical trial progress, regulatory submissions, financing activities, and board appointments throughout the year 2020. It does not contain detailed financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It also is not a transcript, audit report, or legal proceeding update. The document is a narrative summary of corporate activities and milestones, including clinical research updates and financing events, which aligns with a Management Report (MDA) that explains business trends and outlook. The length (over 10,000 characters) and content support classification as a Management Report rather than a brief announcement or regulatory filing. Therefore, the best fit is Management Reports (MDA).
2020-12-31 English
News release - English.pdf
Regulatory Filings
2020-12-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.